ResMed Inc. (RMD) - Breathe easy
November 5, 2024
ResMed Inc. develops, manufactures, distributes, and markets medical device and cloud-based software applications targeting the management of sleep apnoea. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
The company delivered a strong September quarter result, with 11% revenue growth translating to 35% earnings per share growth. Revenues were 3% ahead of consensus due to higher rates of flow generator growth.
The gross margin of 59.2% aligned with expectations, while operating expenses were slightly ahead of forecasts.
Net operating cash flow increased by 14% compared to the previous corresponding period, despite higher inventory due to rebalancing sea versus air freight. Net debt fell, while the value of share buyback program was boosted.
ResMed upped it FY25 EPS guidance thanks to jump higher flow generator revenues. Revenue growth for the current quarter is forecast at 10%. We forecast the company will be able to generate annualised EPS growth of 13% for the next few years, which justifies its current trading multiples. We ticked our price target up from $39.25 to $40.05 following the quarterly.
Insights that count
Discover the best opportunities to outperform the market. Our research team dig deep into the market, company and stock data to bring you insights others might overlook.
Santos (STO) – Game on
Santos produces oil and gas from assets located in Alaska, the Cooper Basin, Queensland and NSW, Papua New Guinea, Western Australia, northern Australia and Timor-Leste.
Rio Tinto (RIO) – No Entrée yet
Rio Tinto Group mines and processes mineral resources worldwide, primarily iron ore, aluminium, and copper, but also other minerals, including lithium.
Qantas Airways (QAN) – Fleet realignment
Qantas Airways provides air transportation services in Australia and internationally, through a fleet of aircraft under the Qantas and Jetstar brands.
.jpg)